Patent 11,400,065 Scope and Claims (US) for Once-Daily Oral Gamma-Hydroxybutyrate (GHB) for Narcolepsy: What the Claims Cover and How Competing Estates Stack Up
Executive summary. US Drug Patent 11,400,065 claims specific methods of treating narcolepsy (and cataplexy/excessive daytime sleepiness) with oral gamma-hydroxybutyrate (GHB) compositions that use (i) timing relative to meals (less than two hours after eating; with dependent timing windows down to immediately after eating/while eating) and (ii) once-daily dosing with dose-proportional PK and a safety profile tied to reduced Cmax behavior and AE timing near Tmax. The claim set is heavily “clinical and PK-defined”: it locks in measurable endpoints (sleep duration ≥6/8/10 consecutive hours; bioequivalence metrics for AUCinf and Cmax under meal-fed vs fasted comparisons; and reduced/altered Cmax “periods” versus a more frequent immediate-release sodium oxybate comparator). The estate’s enforceable scope is primarily method-of-treatment + dosing regimen + product performance characteristics, which narrows design-arounds to different release profiles, different dosing frequency (or non-overnight schedules), and different meal timing that avoids the claimed PK and AE constructs.
US 11,400,065 claims: What methods of treating narcolepsy using oral gamma-hydroxybutyrate are covered?
Core independent claims (as provided). The patent’s independent method claims are directed to treating narcolepsy and associated disorders and symptoms by administering an oral pharmaceutical composition comprising gamma-hydroxybutyrate under defined meal-timing and regimen constraints.
Claim 1: Meal-timing within <2 hours after eating
Claim 1 covers:
- Method of treating narcolepsy and associated disorders/symptoms in a patient in need thereof
- Administering an oral composition comprising GHB
- Timing constraint: administered “less than two hours after eating.”
Claim 1 is the broadest “timing” hook. It does not, on its face, require once-daily dosing, modified release, or specific Cmax/AUC numeric bioequivalence ranges. Those concepts are pulled into dependent claims.
Claim 2: Once-daily dosing + dose proportionality
Claim 2 covers:
- Once daily administration
- Dose proportional composition (explicitly extended through dependent claims to numeric proportionality factors, including Cmax and AUC behavior).
This claim structure matters: it tries to prevent both (i) irregular exposure with dose escalation and (ii) “peak flattening” strategies that could shift proportionality away from the claimed range.
Claim 3: Once-daily dosing + AE timing close to Tmax
Claim 3 covers:
- Once daily administration and
- AE profile construct: “most AEs occur close to Tmax, during the Cmax period.”
Claim 4: Safety reduction via fewer Cmax periods vs immediate-release sodium oxybate
Claim 4 covers:
- Treating narcolepsy/cataplexy/excessive daytime sleepiness by once daily dosing
- Mechanistic PK/safety comparison: the GHB composition has “fewer Cmax periods than an equal dose of immediate release sodium oxybate formulation administered more frequently than once-daily.”
This claim is the strongest design-around gate: it ties scope to comparative Cmax “period” behavior versus the known sodium oxybate immediate-release multi-dose regimen.
Dependent claim expansion: specific schedules and meal windows
Dependent claims further constrain Claim 1 or Claim 2/3/4 to specific timing or regimen details:
- Only once nightly (claims 5, 26, 47, 68, 83, 42)
- Meal timing windows: up to 1.5 hours, 1 hour, 30 minutes, while eating, or immediately after eating (claims 6-10; 27-31; 48-52; 69-73; and similarly under Claim 2 dependent chains)
- Bedtime administration (claims 21, 42, 63, 83)
What specific endpoints (sleep duration, PK, bioequivalence) must be met under US 11,400,065?
The claim set is not limited to “administer less than two hours after eating.” It also includes measurable performance criteria that map to formulation science and clinical PK/PD studies.
Sleep-induction duration endpoints
Claims tie method coverage to achieved sleep duration after administration:
- ≥ 6 consecutive hours (claims 11, 32, 53, 74)
- ≥ 8 consecutive hours (claims 12, 33, 54, 75)
- ≥ 10 consecutive hours (claims 13, 34, 55, 76)
These are outcome-linked limitations. A regimen that produces materially less sleep duration after dosing may not meet the dependent limitations.
PK “similarity” to fasted or ≥2 hours post-meal dosing
Claims include:
- PK profile similar to PK when administered while fasting or at least 2 hours after eating (claims 14, 35, 56, 77)
- AUCinf bioequivalence to fasted/≥2 hours post-meal comparator (claims 15, 36, 57, 78)
- AUCinf bioequivalence with CI constraint: 90% CI within bioequivalence range with “no effect boundaries” (claims 16, 37, 58, 79)
- Cmax bioequivalence to fasted/≥2 hours post-meal comparator (claims 17, 38, 59, 80)
These dependent claims collectively position the patent as protecting not just a dosing rule but a specific exposure matching behavior under fed conditions.
Comparator against immediate-release sodium oxybate split dosing
Claims define further constraints by comparing to immediate-release sodium oxybate liquid dosing at t0 and t4h in equally divided doses (post-meal ≥2 hours):
- AUCinf bioequivalent (claims 18, 39, 60, 81)
- Cmax lower than that comparator (claims 19, 40, 61, 82)
This is a key litigation lever because it ties to a well-defined comparator dosing pattern (two administrations 4 hours apart in immediate-release liquid form).
What formulations and delivery designs are implicated by the claim language?
Although US 11,400,065 is framed as a “method of treating,” dependent claim wording points to specific product architecture.
Modified release formulation requirement
Claims include:
- “composition comprises gamma-hydroxybutyrate in a modified release formulation” (claims 24, 45, 66, 86)
- further split into modified release portion + immediate release portion (claims 25, 46, 67, 87)
That indicates the inventors are protecting a formulation in which exposure is engineered to control Cmax behavior and/or to reduce the number of Cmax periods.
Discrete packaging + mixing step
Claims include a workflow tied to sachets/stick-packs:
- Opening sachet/stick-pack
- Pouring composition out
- Mixing with water after pouring and before oral administration (claims 23, 44, 65, 85)
This suggests the product is (or is intended to be) administered as a reconstituted powder/granule in unit-dose packs, not a ready-to-use liquid.
Dose “amounts equivalent to sodium oxybate”
The claims list specific dose equivalents for GHB:
- 0.5 g, 1.0 g, 1.5 g, 3.0 g, 4.5 g, 6.0 g, 7.5 g, 9.0 g, 10.5 g, 12 g sodium oxybate equivalents (claims 22, 43, 64, 84)
That dose ladder is likely intended to map to clinical dosing strengths used in narcolepsy regimens.
What does “fewer Cmax periods” practically mean for claim coverage and design-around risk?
Claim 4’s “fewer Cmax periods” is a high-information-density limitation. Under the claim language you provided, coverage hinges on demonstrating that the accused regimen produces:
- fewer Cmax periods for the once-daily oral GHB composition
- when compared on an “equal dose” basis to immediate-release sodium oxybate given more frequently than once-daily.
Why this matters for competitors
A competitor attempting to replicate efficacy while reducing AE burden may:
- alter release to create a different Cmax plateau structure (more or less than claimed number of “periods”)
- change dosing frequency (including two nightly doses)
- adjust meal timing so that the fed-state PK does not match the “fasted or ≥2 hours after eating” similarity/bioequivalence constraints.
Those changes can move the product outside dependent claim limitations even if Claim 1’s “<2 hours after eating” is still met.
How broad is the “once daily” dose-proportionality coverage (Claims 2 and dependents)?
The dose-proportionality dependent claims specify numeric ranges and qualitative behavior.
Dose proportionality factor
- “dose proportional by a factor of about 1 to about 1.3 with respect to one or both Cmax and AUC” (claims 88 and 90)
- “composition exhibits proportional increases in plasma levels” (claims 89)
More specific proportionality statements
- “dose proportionality is maintained across the dosage range” (claims 93)
- “Cmax dose proportional across once daily doses of 4.5 g, 6 g, 7.5 g, 9 g” (claim 92)
- “Cmax increases 2.0-fold as the once daily dose increases from 4.5 g to 9 g” (claim 95)
AUC behavior constraints
- AUC dose proportional by factor about 1.3 (claim 101)
- composition has “more dose proportional” AUC than immediate release sodium oxybate (claim 102)
- “AUC increases 2.3-fold as once daily dose increases from 4.5 g to 9 g” (claim 103)
These numerical limitations are enforceability-critical. A competitor whose formulation yields materially different proportionality could fall outside these dependents even if the regimen is once daily.
Orange Book status and US enforcement posture: what is known from the information provided?
No Orange Book listing, FDA approval record, NDA/BLA number, formulation name, or patent listing association is provided. Without those, a reliable mapping of:
- which reference listed drug (RLD) the patent is tied to,
- whether it is a method-of-use patent versus formulation patent in Orange Book,
- or the expiry dates and patent expiration/extended exclusivity schedule
cannot be produced from the provided record.
Accordingly, no accurate litigation timing, exclusivity timeline, or generic entry risk scenario can be stated for the US market based solely on claim text.
Jurisdictional and family landscape: what related patent categories does this claim set imply?
Even without additional bibliographic data, the claim content implies at least four IP “clusters” likely present in the broader portfolio around US 11,400,065:
1) Clinical dosing regimen IP
- meal timing windows after eating
- bedtime-only and once nightly scheduling
- indication scope (narcolepsy, cataplexy, excessive daytime sleepiness)
2) PK-defined fed-state matching IP
- similarity to fasted or ≥2 hours post-meal dosing
- AUCinf and Cmax bioequivalence with numeric CI rules
3) Formulation-release engineering IP
- modified release with modified + immediate release portions
- constraints intended to yield fewer Cmax periods than immediate-release split-dose sodium oxybate
4) Dose-proportionality performance IP
- explicit numeric proportionality behavior across multiple dose strengths
This segmentation is important for freedom-to-operate analysis: design-arounds tend to occur in one cluster and can still infringe dependents anchored to another cluster.
Claim-by-claim scope map: where infringement risk concentrates
Below is a scope map organized around “who is most likely to hit the claims” based on the structure you provided.
Highest-risk regimen match (strongest likelihood of meeting multiple dependents)
- Oral GHB composition
- Dose taken once daily at bedtime
- Administered within <2 hours after eating (including immediate after meals)
- Modified release with modified + immediate release portions
- PK and safety showing:
- AE timing near Tmax/Cmax period
- sleep duration thresholds (≥6/8/10 hours)
- Cmax structure consistent with “fewer Cmax periods” versus IR sodium oxybate split dosing
- dose-proportionality within claimed factor ranges
Intermediate risk
- Meets meal-timing and once-daily, but misses dose-proportionality or sleep-duration thresholds. Infringement could still occur if the competitor’s product meets the relevant dependents for its exact regimen and exposure endpoints.
Lower risk but still plausible under broader claims
- Meets Claim 1’s “<2 hours after eating” but uses a different dosing frequency and different release architecture. The probability of meeting Claim 4 or Claim 2 dependents drops, but dependent Claim 1 does not include the “once daily” limitations.
Key Takeaways
- US 11,400,065 protects an oral gamma-hydroxybutyrate method for narcolepsy with strict meal-timing (less than two hours after eating) and, through dependents, tight once-daily/once-nightly bedtime regimens.
- The patent’s enforceable scope is anchored to measurable PK and clinical endpoints: AUCinf and Cmax bioequivalence (including CI language), PK similarity to fasted or ≥2 hours post-meal dosing, and sleep duration thresholds.
- The claim set targets formulation-release outcomes via a comparative safety construct: “fewer Cmax periods” versus immediate-release sodium oxybate split dosing at t0 and t4h.
- The dose-proportionality dependents include numeric constraints (factor ~1 to 1.3 and specific fold-change examples across 4.5 g to 9 g), which can create design-around opportunities only if the competitor’s exposure scaling falls outside those numerics.
- The provided record does not include Orange Book or FDA/RLD identifiers, so market-exclusivity timelines, expiration dates, and generic/Paragraph IV challenge scenarios cannot be derived without additional bibliographic inputs.
FAQs
-
Does US 11,400,065 require modified release, or is timing alone enough to infringe?
Claim 1 does not expressly require modified release. Modified-release limitations appear in dependent claims tied to formulation architecture.
-
How do the “bioequivalence” dependents change infringement risk for fed dosing strategies?
They require specific fed-state performance (AUCinf/Cmax bioequivalence and CI language) relative to fasted or ≥2 hours post-meal comparators.
-
Can a competitor avoid “fewer Cmax periods” by shifting dosing frequency to twice nightly?
Claim 4 is framed around comparing fewer Cmax periods versus immediate-release sodium oxybate administered more frequently than once-daily; changing frequency may move the product outside that comparative construct, but exact Cmax period structure would still be critical.
-
Do the sleep-duration limitations apply to every covered method?
They are in dependent claims, so they apply only when the asserted claim set includes those dependents or when the competitor’s regimen fits those dependent limitations.
-
What role do dose-strength equivalents (e.g., 4.5 g to 9 g) play in claim coverage?
Those appear in dependent claims listing specific dose equivalents and likely map to the tested strength range for which dose-proportionality and PK constructs are claimed.
References (APA)
- Provided prompt text: “United States Drug Patent 11,400,065” claims list and claim language (no external bibliographic sources cited).
